SURPASS-4: long-term safety data SURPASS-4 extended the evidence to 104 weeks, two full years, in patients with type 2 diabetes inadequately controlled on metformin and/or sulfonylureas
Therefore, an understanding of the long-term economic value of these medications is necessary for patients, providers, and policymakers, and additional studies are needed to assess their lifetime cost-effectiveness
Papaetis GS, Kyriacou A (2022) GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons
If youre serious about weight loss and have tried strategies that havent delivered lasting results, you might wonder whether weight loss medication is a possible solution
Eli Lilly (LLY) Eli Lilly (NYSE:LLY) has emerged as the market leader with its dual-action drugs Mounjaro and Zepbound, both based on tirzepatide, which targets both GLP-1 and GIP receptors
Check pH with strips or a calibrated meter